Gapping up
In reaction to earnings/guidance:
- EXAS +18.7%, PACB +8.3%, BROS +5.9%, ANF +4%, HOLX +2.8%, EXEL +2.3%, CDNA +2.3%, PRMW +2%, RAD +1.7%, CMC +1.6%, RARE +1.5%, EBS +1.4%, CVS +0.9%
Other news:
- CINC +136.8% (CinCor Pharma to be acquired by AstraZeneca (AZN) for $26.00 per share in cash plus a non-tradable CVR of $10.00 per share in cash payable upon a specified regulatory submission of a baxdrostat product)
- AMYT +107.4% ( to be acquired by Chiesi Farmaceutici S.p.A. for $14.50 per ADS)
- ALBO +88.8% (to be acquired by Ipsen (IPSEY) for $42.00 per share plus CVR of $10.00 per share related to the U.S. FDA approval of Bylvay in biliary atresia)
- DAWN +26.3% (Topline Data from Pivotal Phase 2 FIREFLY-1 Trial)
- PAYA +24.5% (Nuvei (NVEI) will acquire Paya in an all-cash transaction at USD $9.75 per share for total consideration of ~$1.3 bln)
- CVAC +24.1% (data on joint COVID-19 and Flu mRNA vaccine development programs)
- GRNA +19% (GreenLight Biosciences and EpiVax Therapeutics signed exclusive collaboration agreement to jointly develop and commercialize personalized mRNA-based vaccine candidates for cancer)
- OCGN +18.5% (results from the Phase 2/3 observer-blind immuno-bridging and broadening study of its COVID-19 vaccine candidate COVAXIN)
- VRDN +9.6% (Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease)
- CBAY +6.4% (collaborates with Kaken Pharmaceutical to develop and commercialize Seladelpar in Japan for primary biliary cholangitis)
- PHAT +6.1% (Topline Results from Phase 3 PHALCON-NERD-301 Trial)
- MRUS +5% (provides milestone update for 2023)
- TRDA +4.9% (announced the selection of a second clinical candidate within its Duchenne franchise ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 45 skipping amenable)
- ANNX +4.6% (Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises)
- TNYA +4.6% (FDA has provided clearance of its Investigational New Drug IND application to initiate clinical testing of TN-201)
- LQDA +4% (enters into a revenue interest financing agreement with HealthCare Royalty for up to $100 million)
- ALVR +2.9% (announces the company's 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapie)
- CVE +2.5% (provides update on Downstream operations)
- XPOF +2.5% (provides in line FY22 guidance and enters into a privately negotiated preferred stock repurchase agreement with certain holders of its outstanding Convertible Preferred Stock)
- AFMD +2.5% (Reports on Corporate Progress and Provides Regulatory Update for AFM13)
- KEX +2.2% (concluded the Company's review of strategic alternatives for its Distribution and Services business which was initiated in early 2022)
- BEAM +2.1% (reports progress across base editing portfolio and outlines key anticipated milestones)
- RVNC +1.7% (receives FDA Acceptance of sBLA for DAXXIFY)
- BLUE +1.5% (Provides Update on Commercial Launch Progress Program Milestones and 2023 Financial Outlook)
Analyst comments:
- BABA +5% (upgraded to Conviction Buy from Buy at Goldman)
- ZG +4.1% (upgraded to Buy from Underperform at BofA Securities)
- WB +2.9% (upgraded to Buy from Neutral at Goldman)
- UBER +2.8% (upgraded to Overweight from Neutral at Piper Sandler)
- ORCL +1.5% (upgraded to Overweight from Neutral at Piper Sandler)
- ALLY +1.2% (upgraded to Neutral from Underweight at Piper Sandler)